Literature DB >> 7564375

Prognosis of breast cancer: evidence for interaction between c-erbB-2 overexpression and number of involved axillary lymph nodes.

I Mittra1, A A Redkar, R A Badwe.   

Abstract

The prognostic significance of c-erbB-2 oncogene amplification or overexpression in relation to axillary lymph node metastasis is controversial. We investigated this question in 159 cases of operable breast cancer: 56 patients with node negative disease and 103 patients with pathological involvement of axillary lymph nodes. c-erbB-2 overexpression was assessed by immunohistochemistry using a polyclonal antibody raised against a synthetic peptide fragment of the oncoprotein. The overall incidence of c-erbB-2 overexpression was 35%. c-erbB-2 overexpression was significantly related to survival when all patients were considered (P = 0.0124), and also for patients with positive axillary lymph nodes (P = 0.0026). c-erbB-2 overexpression had no influence on survival of node negative patients (P = 0.7972). A multivariate survival analysis using the Cox proportional hazard model revealed that number of involved lymph nodes, c-erbB-2 overexpression, ER status, and tumour size were independently related to prognosis (P = 0.0000, 0.0012, 0.0112, and 0.0204, respectively). When an interaction term was introduced in the Cox model between c-erbB-2 overexpression and number of involved axillary lymph nodes, a statistically highly significant interaction between these two factors was observed (P = 0.0002), suggesting that the expression of prognostic power of c-erbB-2 overactivity is related to the number of involved axillary lymph nodes. The 159 patients were then subdivided into three groups: node negative (-ve) (56); 1-6 node positive (+ve) (55); and > or = 7 node +ve (48). This cutoff criterion gave the most numerically equitable distribution of the 159 patients into three groups. The relative risk of death increased stepwise from 0.86 (95% CI 0.26-2.78) for node negative patients, to 1.95 (95% CI 0.82-4.63) for 1-6 node positive patients, to 2.23 (95% CI 1.15-4.35) for > 7 node positive patients. Our results suggest that the prognostic influence of c-erbB-2 overexpression increases arithmatically with increasing number of involved axillary lymph nodes.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7564375     DOI: 10.1002/jso.2930600208

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  6 in total

1.  Hormone Receptors, Her-2/Neu and Chromosomal Aberrations in Breast Cancer.

Authors:  V Dutta; G S Chopra; K Sahai; S K Nema
Journal:  Med J Armed Forces India       Date:  2011-07-21

Review 2.  Signalling between microvascular endothelium and cardiomyocytes through neuregulin.

Authors:  Emily M Parodi; Bernhard Kuhn
Journal:  Cardiovasc Res       Date:  2014-01-29       Impact factor: 10.787

3.  Correlation of ER, PR and HER-2/Neu with other Prognostic Factors in Infiltrating Ductal Carcinoma of Breast.

Authors:  Sepideh Siadati; Majid Sharbatdaran; Novin Nikbakhsh; Naser Ghaemian
Journal:  Iran J Pathol       Date:  2015

4.  Inverse prognostic impact of ErbB2 mRNA and protein expression level in tumors of soft tissue sarcoma patients.

Authors:  Henri Wichmann; Antje Güttler; Matthias Bache; Helge Taubert; Martina Vetter; Peter Würl; Hans J Holzhausen; Alexander W Eckert; Matthias Kappler; Dirk Vordermark
Journal:  Strahlenther Onkol       Date:  2014-04-09       Impact factor: 3.621

5.  S100A14, a member of the EF-hand calcium-binding proteins, is overexpressed in breast cancer and acts as a modulator of HER2 signaling.

Authors:  Chengshan Xu; Hongyan Chen; Xiang Wang; Jidong Gao; Yiqun Che; Yi Li; Fang Ding; Aiping Luo; Shuguang Zhang; Zhihua Liu
Journal:  J Biol Chem       Date:  2013-11-27       Impact factor: 5.157

6.  Number of Axillary Lymph Node Metastases Determined by Preoperative Ultrasound is Related to Prognosis in Patients with Breast Cancer.

Authors:  Yuko Kijima; Heiji Yoshinaka; Munetsugu Hirata; Tadao Mizoguchi; Sumiya Ishigami; Akihiro Nakajo; Hideo Arima; Shinichi Ueno; Shoji Natsugoe
Journal:  Cancers (Basel)       Date:  2010-02-04       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.